Anticalin® Proteins as Therapeutic Agents in Human Diseases

BioDrugs

Volumn 32, Issue 3, 2018, Pages 233-243

  Rothe, Christine ^a   Skerra, Arne ^b  

^a Pieris Pharmaceuticals GmbH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOCAL; ANTICALIN; AZD 1402; FUSION PROTEIN; HEPCIDIN; INTERLEUKIN 4 RECEPTOR ALPHA; LIPOCALIN; PLASMA PROTEIN; PROPROTEIN CONVERTASE 9; PRS 050; PRS 060; PRS 080; PRS 343; SNTICALIN PROTEIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADVANCED CANCER; ANTIBODY SPECIFICITY; ASTHMA; DRUG TARGETING; HUMAN; IMMUNOGENICITY; IRON DEFICIENCY ANEMIA; METABOLIC DISORDER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ENGINEERING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID MALIGNANT NEOPLASM; CHEMISTRY; DISEASES; DRUG THERAPY; GENETICS; MOLECULARLY TARGETED THERAPY; PHARMACEUTICS; PROCEDURES;

BIOPHARMACEUTICS; DISEASE; DRUG THERAPY; HUMANS; LIPOCALINS; MOLECULAR TARGETED THERAPY; RECOMBINANT FUSION PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 85046711793     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-018-0278-1     Document Type: Review

References (70)

1. Åkerström B, Borregaard N, Flower DA, Salier J-S. Lipocalins. Georgetown: Landes Bioscience; 2006.
2. Skerra A. Lipocalins as a scaffold. Biochim Biophys Acta. 2000;1482:337–50.
3. Schiefner A, Skerra A. The menagerie of human lipocalins: a natural protein scaffold for molecular recognition of physiological compounds. Acc Chem Res. 2015;48:976–85.
4. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002;10:1033–43.
5. Huber R, Schneider M, Mayr I, Müller R, Deutzmann R, Suter F, et al. Molecular structure of the bilin binding protein (BBP) from Pieris brassicae after refinement at 2.0 Å resolution. J Mol Biol. 1987;198:499–513.
6. Nunn MA, Sharma A, Paesen GC, Adamson S, Lissina O, Willis AC, et al. Complement inhibitor of C5 activation from the soft tick Ornithodoros moubata. J Immunol. 2005;174:2084–91.
7. Paesen GC, Adams PL, Harlos K, Nuttall PA, Stuart DI. Tick histamine-binding proteins: isolation, cloning, and three-dimensional structure. Mol Cell. 1999;3:661–71.
8. Montfort WR, Weichsel A, Andersen JF. Nitrophorins and related antihemostatic lipocalins from Rhodnius prolixus and other blood-sucking arthropods. Biochim Biophys Acta. 2000;1482:110–8.
9. Skerra A. Imitating the humoral immune response. Curr Opin Chem Biol. 2003;7:683–93.
10. Beste G, Schmidt FS, Stibora T, Skerra A. Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci USA. 1999;96:1898–903.
11. Skerra A. ‘Anticalins’: a new class of engineered ligand-binding proteins with antibody-like properties. J Biotechnol. 2001;74:257–75.
12. Schlehuber S, Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to “anticalins”. Drug Discov Today. 2005;10:23–33.
13. Breustedt DA, Schönfeld DL, Skerra A. Comparative ligand-binding analysis of ten human lipocalins. Biochim Biophys Acta. 2006;1764:161–73.
14. Breustedt DA, Chatwell L, Skerra A. A new crystal form of human tear lipocalin reveals high flexibility in the loop region and induced fit in the ligand cavity. Acta Crystallogr D Biol Crystallogr. 2009;65:1118–25.
15. Breustedt DA, Korndörfer IP, Redl B, Skerra A. The 1.8-Å crystal structure of human tear lipocalin reveals an extended branched cavity with capacity for multiple ligands. J Biol Chem. 2005;280:484–93.
16. Gebauer M, Schiefner A, Matschiner G, Skerra A. Combinatorial design of an Anticalin directed against the extra-domain B for the specific targeting of oncofetal fibronectin. J Mol Biol. 2013;425:780–802.
17. Gebauer M, Skerra A. Anticalins: small engineered binding proteins based on the lipocalin scaffold. Methods Enzymol. 2012;503:157–88.
18. Schönfeld D, Matschiner G, Chatwell L, Trentmann S, Gille H, Hülsmeyer M, et al. An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci USA. 2009;106:8198–203.
19. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
20. Richter A, Eggenstein E, Skerra A. Anticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins. FEBS Lett. 2014;588:213–8.
21. Kim HJ, Eichinger A, Skerra A. High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. J Am Chem Soc. 2009;131:3565–76.
22. Schiefner A, Gebauer M, Richter A, Skerra A. Anticalins reveal high plasticity in the mode of complex formation with a common tumor antigen. Structure. 2018;26:649–56.
23. Barinka C, Ptacek J, Richter A, Novakova Z, Morath V, Skerra A. Selection and characterization of Anticalins targeting human prostate-specific membrane antigen (PSMA). Protein Eng Des Sel. 2016;29:105–15.
24. Richter A, Skerra A. Anticalins directed against vascular endothelial growth factor receptor 3 (VEGFR-3) with picomolar affinities show potential for medical therapy and in vivo imaging. Biol Chem. 2017;398:39–55.
25. ® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models. Biol Chem. 2018;399:235–52.
26. Rauth S, Hinz D, Börger M, Uhrig M, Mayhaus M, Riemenschneider M, et al. High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer β-amyloid peptide. Biochem J. 2016;473:1563–78.
27. Binder U, Matschiner G, Theobald I, Skerra A. High-throughput sorting of an Anticalin library via EspP-mediated functional display on the Escherichia coli cell surface. J Mol Biol. 2010;400:783–802.
28. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967–74.
29. Gille H, Hülsmeyer M, Trentmann S, Matschiner G, Christian HJ, Meyer T, et al. Functional characterization of a VEGF-A-targeting Anticalin, prototype of a novel therapeutic human protein class. Angiogenesis. 2016;19:79–94.
30. Mross K, Fischer R, Richly H, Scharr D, Buechert M, Stern A, et al. First in human phase I study of PRS-050 (Angiocal), a VEGF-A targeting anticalin, in patients with advanced solid tumors: results of a dose escalation study. Mol Cancer Ther. 2011;10:A212.
31. Mross K, Richly H, Fischer R, Scharr D, Buchert M, Stern A, et al. First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors. PLoS One. 2013;8:e83232.
32. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137–43.
33. Masuda Y, Yamaguchi S, Suzuki C, Aburatani T, Nagano Y, Miyauchi R, et al. Generation and characterization of a novel small biologic alternative to proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies, DS-9001a, albumin binding domain-fused Anticalin protein. J Pharmacol Exp Ther. 2018;365:368–78.
34. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.
35. Kato M, He L, McGuire K, Dishy V, Zamora CA. A randomized, placebo controlled, single ascending dose study to assess the safety, PK and PD of DS-9001a, a novel small biologic PCSK9 inhibitor, in healthy subjects. Orlando: ASCPT meeting; 2018.
36. Reichert CO, da Cunha J, Levy D, Maselli LMF, Bydlowski SP, Spada C. Hepcidin: homeostasis and diseases related to iron metabolism. Acta Haematol. 2017;137:220–36.
37. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med. 2011;62:347–60.
38. Slotki I, Cabantchik ZI. The labile side of iron supplementation in CKD. J Am Soc Nephrol. 2015;26:2612–9.
39. Macdougall IC, Bircher AJ, Eckardt KU, Obrador GT, Pollock CA, Stenvinkel P, et al. Iron management in chronic kidney disease: conclusions from a “Kidney Disease: improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2016;89:28–39.
40. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306:2090–3.
41. Hohlbaum AM, Gille H, Trentmann S, Kolodziejczyk M, Rattenstetter B, Laarakkers CM, et al. Sustained plasma hepcidin suppression and iron elevation by Anticalin-derived hepcidin antagonist in cynomolgus monkey. Br J Pharmacol. 2018;175:1054–65.
42. Renders L, Wen M, Dellanna F, Heinrichs S, Budde K, Rosenberger C, et al. Safety, tolerability, and pharmacodynamics of the hepcidin antagonist PRS-080#022-DP after single administration—a phase Ib study in anemic chronic kidney disease patients undergoing hemodialysis. Mannheim: Poster, Congress for Nephrology; 2017.
43. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.
44. Bagnasco D, Ferrando M, Varricchi G, Puggioni F, Passalacqua G, Canonica GW. Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med (Lausanne). 2017;4:135.
45. Parulekar AD, Kao CC, Diamant Z, Hanania NA. Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs. Curr Opin Pulm Med. 2018;24:50–5.
46. Barranco P, Phillips-Angles E, Dominguez-Ortega J, Quirce S. Dupilumab in the management of moderate-to-severe asthma: the data so far. Ther Clin Risk Manag. 2017;13:1139–49.
47. Anderson GP, Hohlbaum A, Jensen K, Bähre A, Gille H. Discovery of PRS-060, an inhalable CD123/IL4Ra/TH2 blocking anti-asthmatic anticalin protein re-engineered from endogenous lipocalin-1. Eur Respir J. 2015;46:OA3256.
48. Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: combinations in the clinic. Front Oncol. 2014;4:385.
49. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1–10.
50. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.
51. Giuroiu I, Weber J. Novel checkpoints and cosignaling molecules in cancer immunotherapy. Cancer J. 2017;23:23–31.
52. Chester C, Sanmamed MF, Wang J, Melero I. Immunotherapy targeting 4–1BB: mechanistic rationale, clinical results, and future strategies. Blood. 2017;131:49–57.
53. Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer. 2014;2:7.
54. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest. 2012;122:1066–75.
55. Ye Q, Song DG, Poussin M, Yamamoto T, Best A, Li C, et al. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res. 2014;20:44–55.
56. + melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One. 2013;8:e60031.
57. Hinner MJ, Bel Aiba RS, Jaquin T, Berger S, Dürr M, Schlosser C et al. Tumor localized costimulatory T cell engagement by the 4-1BB/HER2 bispecific antibody-Anticalin fusion PRS-343 (manuscript in preparation).
58. Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39–51.
59. Hinner MJ, Aiba R-SB, Wiedenmann A, Schlosser C, Allersdorfer A, Matschiner G, et al. Costimulatory T cell engagement via a novel bispecific anti-CD137/anti-HER2 protein. J Immunother Cancer. 2015;3:P187.
60. Nakatsura T, Nishimura Y. Usefulness of the novel oncofetal antigen glypican-3 for diagnosis of hepatocellular carcinoma and melanoma. BioDrugs. 2005;19:71–7.
61. He H, Fang W, Liu X, Weiss LM, Chu PG. Frequent expression of glypican-3 in Merkel cell carcinoma: an immunohistochemical study of 55 cases. Appl Immunohistochem Mol Morphol. 2009;17:40–6.
62. Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004;251(Suppl 2):II/4–II/9.
63. Getts DR, Getts MT, McCarthy DP, Chastain EM, Miller SD. Have we overestimated the benefit of human(ized) antibodies? MAbs. 2010;2:682–94.
64. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89:4285–9.
65. Salazar-Fontana LI, Desai DD, Khan TA, Pillutla RC, Prior S, Ramakrishnan R, et al. Approaches to mitigate the unwanted immunogenicity of therapeutic proteins during drug development. AAPS J. 2017;19:377–85.
66. Deehan M, Garces S, Kramer D, Baker MP, Rat D, Roettger Y, et al. Managing unwanted immunogenicity of biologicals. Autoimmun Rev. 2015;14:569–74.
67. Gokemeijer J, Jawa V, Mitra-Kaushik S. How close are we to profiling immunogenicity risk using in silico algorithms and in vitro methods? An industry perspective. AAPS J. 2017;19:1587–92.
68. FDA. Guidance for Industry: Immunogenicity Assessment for Therapeutic Protein Products. US Department of Health and Human Services. 2014.
69. Schlehuber S, Skerra A. Duocalins: engineered ligand-binding proteins with dual specificity derived from the lipocalin fold. Biol Chem. 2001;382:1335–42.
70. Gebauer M, Skerra A. Alternative protein scaffolds as novel biotherapeutics. In: Rosenberg A, Demeule B, editors. Biobetters—protein engineering to approach the curative. New York: Springer; 2015. p. 221–68.